Mike Lau

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Christopher P. Vellano, Michael G. White, Miles C. Andrews et al. · Nature · 2022 · 130 citations · Full text

Life Sciences, Molecular Biology, Oncology +12

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

Kevin J. Harrington, A. Berrier, Martin Robinson et al. · European Journal of Cancer · 2012 · 118 citations

Medicine, Oncology, Radiation Oncology +7

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer

Azeem Saleem, Graham E. Searle, Laura Kenny et al. · EJNMMI Research · 2015 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17

cDNA Cloning of a Third Human C2-Domain-Containing Class II Phosphoinositide 3-Kinase, PI3K-C2γ, and Chromosomal Assignment of This Gene (PIK3C2G) to 12p12

Magdalena Rozycka, Yong‐Jie Lu, Richard A. Brown et al. · Genomics · 1998 · 63 citations

Life Sciences, Genetics, Molecular Biology +10

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Victoria Atkinson, Shahneen Sandhu, Geke A.P. Hospers et al. · Melanoma Research · 2020 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +14